23.01
5.88%
1.2525
Enliven Therapeutics Inc 주식(ELVN)의 최신 뉴스
(ELVN) Proactive Strategies - Stock Traders Daily
Enliven Therapeutics director sells $28,458 in company stock By Investing.com - Investing.com Australia
Enliven Therapeutics director sells $28,458 in company stock By Investing.com - Investing.com Canada
Enliven Therapeutics director sells $28,458 in company stock By Investing.com - Investing.com UK
Enliven Therapeutics Announces Details Regarding the - GlobeNewswire
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML - StockTitan
Enlight Renewable Energy (NASDAQ:ENLT) Trading Up 3.8% - MarketBeat
Enlight Renewable Energy (NASDAQ:ENLT) Shares Gap Down to $16.73 - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc.ENFN - PR Newswire
Bank of New York Mellon Corp Buys 37,632 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
First Turn Management LLC Purchases New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics, Inc. Forecasted to Post Q3 2024 Earnings of ($0.46) Per Share (NASDAQ:ELVN) - Defense World
Enliven Therapeutics Inc [ELVN] Insider Activity: An Update for Investors - Knox Daily
HC Wainwright Comments on Enliven Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ELVN) - MarketBeat
Research Analysts Offer Predictions for Enliven Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:ELVN) - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) to Post Q1 2025 Earnings of ($0.52) Per Share, HC Wainwright Forecasts - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at HC Wainwright - Defense World
HC Wainwright Initiates Coverage on Enliven Therapeutics (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Trading Up 8.9% - MarketBeat
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst - Yahoo Finance
Enliven Therapeutics stock starts at Buy with H.C. Wainwright; sees potential in next-gen cancer treatments - Investing.com Canada
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? - MSN
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? - Yahoo Finance
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Joseph P. Lyssikatos Sells 12,000 Shares of Stock - Defense World
Enliven Therapeutics executive sells over $269k in stock - Investing.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $269,880.00 in Stock - MarketBeat
Enliven Therapeutics executive sells over $269k in stock By Investing.com - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Shares Up 4.8% - MarketBeat
How the (ELVN) price action is used to our Advantage - Stock Traders Daily
Enliven Therapeutics CFO sells over $95k in company stock - Investing.com India
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 4,250 Shares of Stock - MarketBeat
Enliven Therapeutics CEO sells $274k in company stock By Investing.com - Investing.com Australia
Enliven Therapeutics CFO sells over $95k in company stock - Investing.com
Enliven Therapeutics CEO sells $274k in company stock - Investing.com India
Enliven Therapeutics CEO sells $274k in company stock - Investing.com
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
An Analysis of Enliven Therapeutics Inc (ELVN)’s Potential Price Growth - Knox Daily
New Raf kinase inhibitors disclosed in Enliven Therapeutics patent - BioWorld Online
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q2 2024 - MSN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 Shares - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 Shares - MarketBeat
Enliven Therapeutics director sells over $29k in company stock - Investing.com
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4% - MarketBeat
Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet - MSN
Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet - Yahoo Canada Finance
Lifesci Capital Weighs in on Enliven Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ELVN) - Defense World
Q3 2024 EPS Estimates for Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increased by Analyst - MarketBeat
Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet - Yahoo Finance
Enliven Therapeutics (NASDAQ:ELVN) Releases Quarterly Earnings Results, Beats Expectations By $0.17 EPS - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up to $21.52 - MarketBeat
Enliven Therapeutics begins patient dosing in oncology drug trial - BizWest
Enliven Therapeutics stock holds Buy rating from TD Cowen on strong trial prospects - Investing.com Canada
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q2 2024 - InvestorPlace
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update - BioSpace
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update - GlobeNewswire
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update - Yahoo Finance
Vanguard Group Inc. Sells 47,622 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Vanguard Group Inc. Sells 47,622 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Trading (ELVN) With Integrated Risk Controls - Stock Traders Daily
Reviewing RAPT Therapeutics (NASDAQ:RAPT) & Enliven Therapeutics (NASDAQ:ELVN) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 11.4% Following Insider Selling - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 991 Shares - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Joseph P. Lyssikatos Sells 3,099 Shares of Stock - Defense World
Enliven Therapeutics CEO sells $62,555 in company stock - Investing.com India
Enliven Therapeutics executive sells shares worth over $85k - Investing.com India
Enliven Therapeutics executive sells shares worth over $85k By Investing.com - Investing.com UK
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 991 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 11.4% - MarketBeat
Enliven Therapeutics executive sells shares worth over $85k - Investing.com
Enliven Therapeutics director sells over $64k in company stock - Investing.com
자본화:
|
볼륨(24시간):